Biogen’s controversial Alzheimer’s disease therapy was approved by US regulators, a landmark decision that stands to dramatically change treatment for the debilitating brain condition.
The US Food and Drug Administration granted the antibody therapy an accelerated approval, which means Biogen will need to conduct more research to establish the drug’s benefits for it to remain on the market.
